As CEO of Myovant Sciences, the biopharmaceutical company developing the novel hormonal treatment relugolix for men with advanced prostate cancer, Seely knows that the disease occurs more often in Black men than it does in White men, killing them at a higher rate.
She also knows that the COVID-19 pandemic has created barriers for all men with prostate cancer because social distancing has closed many of the places they go for information and support. Compounding this problem is the fact that COVID-19 and its complications have disproportionately affected the Black community.
For those reasons, Myovant Sciences teamed up with three other organizations to form Forward Momentum, a men’s health coalition with the goal of improving the lives of patients with prostate cancer.
“Our men’s health program is really focused on health disparities and, in particular, African American men,” Seely said. “Oftentimes, they’re not adequately studied, they’re not adequately researched, and
You’ve reached your free article limit
Subscribe to enjoy unlimited access to trusted journalism. Cancel anytime.
Subscribe nowNeed help? molokom@insidepolitic.co.za
